MedTrace Logo

Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

NCT04308694 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-01

Study results available
· View outcomes & findings →

Summary

The overarching goal of this pilot study is to explore the feasibility, acceptability, and patient/provider satisfaction of pharmacy-based administration and dispensing of methadone for opioid use disorder. The results gained will inform the development of a future multisite randomized clinical trial.

Conditions

  • Opioid-use Disorder

Interventions

DRUG

Pharmacy-based methadone administration and dispensing

Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.

Sponsors & Collaborators

  • Duke Health

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Friends Research Institute, Inc.

    lead OTHER

Principal Investigators

  • Li-Tzy Wu, ScD · Duke Health

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2021-01-05
Completion
2021-01-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04308694 on ClinicalTrials.gov